clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Pyelonephritis D011704 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Rickettsia Infections D012282 5 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Syphilis D013587 6 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Skin Ulcer D012883 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Whooping Cough D014917 6 associated lipids
Bronchitis D001991 6 associated lipids
Bacteriuria D001437 7 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bronchiectasis D001987 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chlamydia Infections D002690 7 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Metaplasia D008679 7 associated lipids
Klebsiella Infections D007710 7 associated lipids
Tooth Discoloration D014075 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Stomach Diseases D013272 7 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Fistula D005402 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Leprosy D007918 8 associated lipids
Sinusitis D012852 9 associated lipids
Bacteremia D016470 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Huang JQ et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. 2005 World J. Gastroenterol. pmid:15884111
Gumurdulu Y et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. 2004 World J. Gastroenterol. pmid:14991935
Guo CY et al. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. 2004 World J. Gastroenterol. pmid:14991953
Mirbagheri SA et al. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. 2006 World J. Gastroenterol. pmid:16937475
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Miehlke S et al. Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). 2001 World J. Gastroenterol. pmid:11819768
Trifan A et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. 2013 World J. Gastroenterol. pmid:24259981
Babic Z et al. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. 2005 World J. Gastroenterol. pmid:15884110
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Ji F et al. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. 2006 World J. Gastroenterol. pmid:16586550
Sereni G et al. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22969227
Aydemir S et al. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15682477
Wang CH et al. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. 2015 World J. Gastroenterol. pmid:26494972
Zhao LJ et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. 2014 World J. Gastroenterol. pmid:24782630
Gao XZ et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. 2010 World J. Gastroenterol. pmid:20818821
Pan W et al. Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. 2013 Xenobiotica pmid:22830954
Kanayama N et al. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. 2007 Xenobiotica pmid:17484517
Burt HJ et al. IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. 2010 Xenobiotica pmid:20230210
Kubo JI et al. Pharmacokinetic evaluation of high pulmonary disposition of clarithromycin after systemic administration. 2002 Xenobiotica pmid:12419017
Yamamoto T et al. Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models. 2005 Xenobiotica pmid:16192112